Recorded Presentation from the NCCN 2016 Congress Webinar Series: Breast Cancer - Supportive Care: Fertility Preservation & Use of Bone Modifying Agents in Patients with Breast Cancer
Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The clinical evaluation and therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. Healthcare professionals need to be educated on current and emerging scientific data to make evidence-based treatment decisions, to communicate treatment options to patients effectively in order to make shared treatment decisions, and to provide optimal care for patients with breast cancer.
As the complexity and importance of screening, testing, and individualized treatment strategies for breast cancer have increased, so has clinicians’ reliance on the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines and NCCN’s educational interventions to increase knowledge and bridge the gaps between knowledge and competence.
This webinar series will provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines for Breast Cancer, to ensure that oncologists and other oncology healthcare professionals have a clear understanding of breast cancer diagnosis, staging and initial therapy, radiation therapy in the management of locoregional disease, adjuvant therapy for locoregional disease, and metastatic disease management.
This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with breast cancer.
Following this activity, participants should be able to:
- Discuss fertility preservation options with patients to inform treatment decision making.
- Counsel patients about the supportive and therapeutic role of antiresorptive agents for the management of bone health.
Joanne Frankel Kelvin, MSN, RN, CNS, AOCN
Memorial Sloan Kettering Cancer Center
John Ward, MD
Huntsman Cancer Institute at the University of Utah
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below have no relevant financial relationships to disclose:
Joanne Frankel Kelvin, MSN, RN, CNS, AOCN
The faculty listed below have disclosed the following relevant financial relationships:
John Ward, MD
Galena Biopharma, Inc: Scientific Advisor
NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Kathy Smith, CMP, CHCP; Jennifer McCann Weckesser
The NCCN clinical information team listed below, who has reviewed content, has no relevant financial relationships to disclose:
Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Dorothy Shead, MS
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.84 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-054-H01-P
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.84 ANCC contact hours
- 0.75 Participation